Detalhe da pesquisa
1.
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.
Cardiovasc Diabetol
; 22(1): 233, 2023 08 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-37653496
2.
Observational evidence from patients diagnosed with chronic lymphocytic leukaemia (CLL) in Finland between 2005-2015 show improved survival over time.
Eur J Haematol
; 103(3): 190-199, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31210368
3.
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
Diabetes Metab
; 49(2): 101418, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36608816
4.
Healthcare resource utilization in patients treated with empagliflozin in East Asia.
J Diabetes Investig
; 13(5): 810-821, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-34859609
5.
Prevalence of adverse pregnancy outcomes after exposure to interferon beta prior to or during pregnancy in women with MS: Stratification by maternal and newborn characteristics in a register-based cohort study in Finland and Sweden.
Mult Scler Relat Disord
; 48: 102694, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33429303
6.
Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study.
Endocrinol Diabetes Metab
; 4(1): e00183, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33532619